Biotech Stocks
Last updated:
Biotech stocks include companies that use biology to discover and develop medicines, diagnostics and research tools. Their value may depend on a small number of scientific programmes, which makes clinical evidence, regulatory progress, cash runway and intellectual property central to analysis.
The category ranges from pre-revenue developers to commercial businesses with approved products, so risk and valuation should be assessed at the individual company level.
List of Biotech Stocks
Which Biotech Stocks are gaining or losing interest?
Based on INDmoney Data: Search interest and investment activity.
Top Biotech Stocks by Search Interest
INDmoney Data - Aug 1, 2026 to Sep 1, 2026
Stock | Monthly Change |
|---|---|
 Sionna Therapeutics, Inc. | 3711.00% |
 OmniAb | 2037.00% |
 Moderna | 1542.00% |
 Celularity | 1593.00% |
 Beyondspring | 1344.00% |
Top Biotech Stocks by Investment Interest
INDmoney Data - Aug 1, 2026 to Sep 1, 2026
Stock | Monthly Change |
|---|---|
OmniAb | 14700.00% |
Sionna Therapeutics, Inc. | 8725.00% |
 Quoin Pharmaceuticals | 1120.00% |
Moderna | 793.70% |
 Exelixis | 338.46% |
Which Biotech Stocks Gained or Fell the Most in the Last Month?
Based on 1 month return. Aug 1, 2026 to Sep 1, 2026
Top Monthly Gainers
Stock | Monthly Change |
|---|---|
Celularity | 148.70% |
Moderna | 151.71% |
 Capricor Therapeutics | 149.09% |
 FibroBiologics, Inc. | 105.71% |
OmniAb | 125.76% |
Top Monthly Losers
Stock | Monthly Change |
|---|---|
Sionna Therapeutics, Inc. | -87.55% |
 Curis | -70.32% |
 CalciMedica | -53.56% |
 TransCode Therapeutics | -52.19% |
Beyondspring | -42.14% |
What are Biotech Stocks?
Biotech stocks are shares of companies applying biological science to create treatments, tests, platforms or tools. Many focus on areas such as antibodies, cell and gene therapy, vaccines, RNA-based medicines or precision diagnostics. Early-stage firms may spend for years on research before generating product revenue.
Commercial biotech companies can resemble pharmaceutical businesses once they have approved medicines, but may remain concentrated in a smaller product portfolio or technology platform.
How do Biotech Companies Make Money?
A biotech company can sell an approved product directly, share profit with a partner, license a programme or receive milestone and royalty payments. Before approval, funding often comes from equity, debt or collaboration payments rather than customer revenue.
A partnership can reduce development cost and provide validation, but it also gives away part of the economics. Investors should distinguish recurring product sales from one-time upfront or milestone revenue, which can make reported growth appear stronger than the underlying commercial business.
How Does the Biotech Development Process Affect Investors?
Potential medicines move through laboratory research, human trials and regulatory review. Each stage tests different questions around safety, dose and effectiveness, and failure remains possible even after encouraging early data. Trial design, patient selection, endpoint quality and comparison with the current standard of care matter more than headline percentages alone.
Approval is not the final step: pricing, reimbursement, manufacturing and physician adoption determine whether a scientifically successful product becomes a commercial success.
Should You Invest in Biotech Stocks?
Biotech stocks may suit investors seeking exposure to successful drug innovation who can tolerate clinical failure, dilution and binary outcomes. They may be less suitable for investors who need predictable returns or do not want to monitor category-specific drivers.
Before investing, compare:
- Map each important programme by development stage, target population, clinical evidence, next milestone and competitive alternatives.
- Review the company’s cash and expected spending to estimate runway without assuming future fundraising will be easy.
- Check patent protection, manufacturing complexity, safety signals and dependence on a single asset.
- For commercial companies, study patient growth, net pricing and profitability.
- Probability-adjusted thinking is essential because a pipeline should not be valued as if every programme will reach the market.
Frequently Asked Questions (FAQs) about Biotech Stocks:
Biotech traditionally refers to medicines developed using biological systems, while pharma historically focused more on chemical drugs. In practice, the lines overlap, and company stage and portfolio breadth are often more useful distinctions.
Clinical data, regulatory decisions, financing and safety findings can materially change the expected value of a programme in one day. Small companies may depend on only one or two assets.
The pipeline is the set of drug or diagnostic candidates a company is developing. Investors should examine stage, evidence, target market, competition, cost and ownership for each major programme.
They can offer exposure to successful drug innovation, but returns depend on company quality, entry valuation and clinical failure, dilution and binary outcomes.
Map each important programme by development stage, target population, clinical evidence, next milestone and competitive alternatives. Review the company’s cash and expected spending to estimate runway without assuming future fundraising will be easy.
Individual stocks give you control over company selection and valuation but add company-specific risk. A related ETF can spread exposure across several holdings. Compare the ETF's holdings, concentration, expense ratio and liquidity before deciding.
Trial failure, safety issues, regulatory rejection, manufacturing problems, patent disputes, competition and dilution are key risks. Scientific promise does not remove financing or commercial risk.